ArticlePest management science2026
Dose-dependent efficacy of a novel dsRNA-based solution containing vadescana for Varroa destructor control.
Article in Pest management science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundA novel dsRNA-based product, containing a molecule called vadescana, interferes with Varroa destructor (Anderson and Trueman) fecundity and shows promise as a new biopesticide strategy for Varroa management. This study defines optimal dosing rates for vadescana in the field by evaluating efficacy in full-sized honey bee (Apis mellifera Linneas) hives to contribute essential preliminary information for vadescana development and implementation. Additionally, this study examined the impacts of various doses of vadescana on colony health by counting frames of bees and brood.
resultsVarious concentrations, application volumes, and regimens (single or split application 3 weeks apart) of vadescana (2, 4, or 8 g/L) were applied to colonies and impacts were compared to colonies left untreated or treated with amitraz (positive control). Vadescana (4 g/L) applied at 4 g per brood box in a single dose was most effective at reducing Varroa populations for up to 18 weeks. Colony populations (average number of frames of bees and brood) remained unaffected among treatments over time.
conclusionThe results presented provide critical information for the development of vadescana by defining an optimal dose to use in full-size honey bee colonies and supporting claims of insignificant honey bee colony-level impacts. This study also introduces further research needs for broader applications and future deployment of this dsRNA-based Varroa management option. © 2026 The Author(s). Pest Management Science published by John Wiley & Sons Ltd on behalf of Society of Chemical Industry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.